Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
121.20
+1.89 (1.58%)
At close: Aug 13, 2025, 4:00 PM
120.60
-0.60 (-0.50%)
After-hours: Aug 13, 2025, 7:33 PM EDT
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.25
Revenue / Employee
$727,251
Employees
75,883
Market Cap
234.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
NVS News
- 1 day ago - Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - GlobeNewsWire
- 2 days ago - Swiss government to meet pharma firms to discuss US tariffs - Reuters
- 2 days ago - Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease - WSJ
- 2 days ago - Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - PRNewsWire
- 7 days ago - Novartis weighs deal for biotech Avidity Biosciences, FT reports - Reuters
- 12 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 13 days ago - Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use - PRNewsWire
- 13 days ago - Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says - Forbes